US8086442071 - Common Stock
SCIENCE 37 HOLDINGS INC
NASDAQ:SNCE (3/11/2024, 6:05:35 PM)
After market: 5.7203 -0.03 (-0.52%)5.75
+0.02 (+0.35%)
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
SCIENCE 37 HOLDINGS INC
800 Park Offices Drive, Suite 3606
RESEARCH TRIANGLE PARK NORTH CAROLINA
P: 19843773737
CEO: Andrew McDonald
Employees: 460
Website: https://lifesciacquisition.com
Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry
19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials....
Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities....
Here you can normally see the latest stock twits on SNCE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: